A Cardiological Sojourn in Bangladesh writes Dr Ian Jeffery from Canberra

Associate Professor Atifur Rahman is a cardiologist at the Gold Coast Hospital. A medical graduate from Bangladesh he continues to maintain a close association with the cardiology community in Bangladesh and to be involved in their education programmes. I first met Atifur when I examined him for part of his clinical FRACP exams. Atifur then undertook his advanced training in cardiology at The Canberra Hospital where I was fortunate to be his clinical supervisor.

Recently I was invited to join Atifur to travel to Bangladesh to participate in a series of five cardiology seminars across the country. Our travel was sponsored by Beximco Pharma – one of the largest pharmaceutical manufacturers in Bangladesh. For me, and my wife who also came, it was a wonderful experience as well as a great adventure. My presentation focused on the evidence for varying pharmacologic interventions for the primary prevention of cardiovascular disease and Atifur spoke on recent advances in coronary intervention – “From prevention to intervention.”
More...

Antibiotics and Micronutritional Blend to Enhance Fertility Potential in Male Having Abnormal Semen Parameters

Mosammat Rashida Begum^*,1, David Miller², M.A. Salam³, Ehsan Quadir⁴, Mosammat Sahina Begum⁵, Farzana Khan⁵ and Zahid Hassan Bhuiyan<sup>6

1</sup> Dhaka Medical College, Dhaka, Bangladesh
² University of Leeds, Leeds UK
³ BSMMU, Dhaka, Bangladesh
⁴ Sir Salimullah Medical College, Bangladesh
⁵ Infertility Care and Research Centre (ICRC), Dhaka, Bangladesh
⁶ Bangladesh Medical College, Bangladesh
More...

The FDA and Safe Use of Long-Acting Beta-Agonists in the Treatment of Asthma
Badrul A. Chowdhury, M.D., Ph.D., and Gerald Dal Pan, M.D., M.H.S.

For over a decade, the Food and Drug Administration (FDA) and the medical community have discussed how to safely use long-acting beta-agonists (LABAs) — drugs designed to provide bronchodilation for 12 hours or longer through stimulation of the β2-adrenergic receptor.1 Even before U.S. approval of the first LABA, there was concern about a paradoxical increase in serious asthma exacerbations in some patients treated with these drugs.
More...